<DOC>
	<DOCNO>NCT02284854</DOCNO>
	<brief_summary>Open-label study two parallel group 20 healthy subject . Group A assessed effect CBZ ESL pharmacokinetics , Group B assess effect ESL CBZ pharmacokinetics .</brief_summary>
	<brief_title>Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate Carbamazepine</brief_title>
	<detailed_description>Open-label study two parallel group 20 healthy subject . Group A assessed effect CBZ ESL pharmacokinetics , Group B assess effect ESL CBZ pharmacokinetics . Each patient participate study approximately 9 week . The clinical portion study complete approximately 3 month . Subjects receive treatment 35 day .</detailed_description>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Male female subject age 18 45 year inclusive ; Body mass index ( BMI ) 18 30 kg/m2 inclusive ; Healthy determine prestudy medical history , physical examination , vital sign , 12lead electrocardiogram ( ECG ) ; negative test Hepatitis B surface Antigen ( HBsAg ) , antiHCVAb Human Immunodeficiency Virus ( HIV ) 1 HIV2 Ab screening ; Clinical laboratory test result clinically acceptable screen admission treatment period ; Negative screen alcohol drug abuse screen admission treatment period ; Nonsmokers exsmokers ; Able willing give write informed consent ; If female , childbearing potential reason surgery , childbearing potential , use doublebarrier method contraception : 1 male barrier method [ male condom ] plus 1 female barrier method ( diaphragm , spermicide , intrauterine device ) ; If female , negative urine pregnancy test screen admission treatment period . Clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder ; clinically relevant surgical history ; History relevant atopy drug hypersensitivity ( include know hypersensitivity ESL carboxamide derivative [ e.g. , carbamazepine , oxcarbazepine ] excipients ; know hypersensitivity drug structurally relate carbamazepine [ e.g . : tricyclic antidepressant ] excipients ) ; Second thirddegree atrioventricular blockade correct pacemaker clinically significant abnormality 12lead ECG determine investigator ; History alcoholism drug abuse ; Consumed 14 units1 alcohol week ; Significant infection know inflammatory process screen admission treatment period ; Acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhoea , heartburn ) time screen admission treatment period ; Use medicine within two week admission first period may affect safety study assessment , investigator 's opinion ; Had donate receive blood blood product within 3 month prior screen ; Vegetarians , vegan medical dietary restriction ; Could communicate reliably investigator ; unlikely cooperate requirement study ; Unwilling unable give write informed consent ; If female , pregnant breastfeeding ; If female , childbearing potential use accept effective contraceptive method use hormonal contraceptive ; Had receive investigational drug within 3 month screen currently participate another study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>